-selected stem cell boost for delayed orinsuff i cient engraftment after allogeneicstem cell transplantationAA Oyekunle 1+ , U Koehl 2 , H Schieder 1 , F Ayuk 1 , H Renges 1 , N Fehse 1 , T Zabelina 1 ,B Fehse 1 , T Klingebiel 2 , A Sputtek 3 , AR Zander 1 and N Kro¨...
CD34 + 2selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transp lantation [ J ]. Cytotherapy, 2006, 8 ( 4) : 375 - 380.Oyekunle A A,Koehl U,Schieder H,et al.CD34^+-selected stem cell boost for delayed or insufficient engraftment after ...
et al. Correction to: CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease. Bone Marrow Transplant 57, 1855 (2022). https://doi.org/10.1038/s41409-022-01854-9 Download citation Published19 October 2022 Issue DateDecember ...
CD34 (+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological... Faucher,Bacher,El-Cheikh,... - 《Biology of Blood & Marrow Transplantation Journal of the American Society for Blood & Marrow Transplant...
Boost characteristics are shown in Table 1. Table 1. CD34+ Stem Cell Boost Characteristics PatientAge at Boost(yr)Initial Onset of Mixed Chimerism(days after HSCT)Day of Boost (Post-HSCT)Time to Boost from Onset of Mixed Chimerism(days)CD34+ Stem Cell Dose(106/kg)CD3 T Cell ...
In summary, we established a protocol to boost the expansion of CD34(+) and CD133(+) cells. Thereby we provide a technical step towards the clinical application of autologous stem cell transplantation. 展开 关键词: Endothelial progenitor cells platelet-released growth factors PRGF tissue engineering...
day +60 no aGVHD occurred. At that time point, seven patients received 2 × 106/kg CD3+cells while CsA had been tapered to 50% of the starting dose. One of these patients died after a second T cell boost given on day +90 without concomitant immunosuppression due to grade IV intest...
Meyer GP, Wollert KC, Lotz J, Pirr J, Rager U, Lippolt P, Hahn A, Fichtner S, Schaefer A, Arseniev L, Ganser A, Drexler H (2009) Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 30:2978–...
We conducted a prospective phase II trial utilizing the CliniMACs system to perform CD34+-cell selection of PBSCs from haploidentical donors to evaluate engraftment and hematoimmunological reconstitution. In total, 21 children with hematological malignancies or nonmalignant conditions underwent conditioning ...
Our results demonstrate that giving a boost to canonical Wnt signaling, triggered by transient exposure to Wnt3a or LiCl, the differentiation capacity of thymic progenitors changes, enhancing NK cell production. On the contrary, Wnt3a- or LiCl-pretreated thymic progenitors generate a significantly ...